Wuhan Institute of Biological Products Co., Ltd clinical trials
Acquired by Sinopharm, Nov 2010 · source ↗
The registry lists 3 studies whose lead sponsor is Wuhan Institute of Biological Products Co., Ltd. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 2, 2022.
Before and after it joined Sinopharm
- First submitted before Wuhan Institute of Biological Products Co., Ltd became part of Sinopharm
- 0
- First submitted after Wuhan Institute of Biological Products Co., Ltd became part of Sinopharm
- 3
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Wuhan Institute of Biological Products Co., Ltd3 studies
Something wrong with this grouping? Tell us on the Sinopharm page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All Sinopharm studies →
- Clinical Study of F61 Injection in Healthy Chinese SubjectsStatus unknownNCT05483504Phase 1
Sponsor listed in the registry: Wuhan Institute of Biological Products Co., Ltd · First submitted after Wuhan Institute of Biological Products Co., Ltd became part of Sinopharm
- To Identify the Immunogenicity and Safety of QIV in Children Aged 3-8 YearsStatus unknownNCT05389137Phase 4
Sponsor listed in the registry: Wuhan Institute of Biological Products Co., Ltd · First submitted after Wuhan Institute of Biological Products Co., Ltd became part of Sinopharm
- A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19Status unknownNCT05381519Phase 2
Sponsor listed in the registry: Wuhan Institute of Biological Products Co., Ltd · First submitted after Wuhan Institute of Biological Products Co., Ltd became part of Sinopharm